Exchange: NASDAQ·Updated 04:30 PM EST
LRMR logo

LRMR Larimar Therapeutics Inc

$3.20
$0.08
(2.48%)
Today
Closed $3.14
$0.06
(1.91%)
After Hours
Reported EarningsNov 16
Mkt Cap$336.92M
Vol1.71M

About LRMR

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. It also engages in the research, development, and commercialization of novel therapeutics for mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
54

Neutral Sentiment

How do you feel about LRMR?

OldManLogan
$LRMR Key takeaways summary: 1) Approval mid 2027, launch Q3 2027 in US; then launching in outside US markets around a year later I believe. 2) Nomla would be the only approved treatment for FA for patients under 16, so I don't doubt that they would get priority review 3) They have requested a PRV Voucher as a part of the BLA submission, which could bring in as much as $200M+ once approved 4) $130M in cash and company plans royalty deals or some strategic outlicensing to bridge that gap; so I'd expect to hear about a royalty deal soon...
7
PaytiencePaysGreen
$LRMR great news on the filing. I sure hope not going to be RTF in 2027. Refusal to file will be horrendous
2
1
OldManLogan
$LRMR If Deerfield is shopping Larimar around for an acquisition, it should have a catchy tagline like "Like the FA drug that Biogen bought for $7B, but this one actually works."
5
OldManLogan
$LRMR I've said it before but the math says that LRMR is a candidate for an epic short squeeze; tutes and insiders hold 96% of the shares in the company leaving retailers with just 4% of the float. Meanwhile, short position is in the 16-20% range... it will be very difficult shorts to cover anywhere close to the current price...
6
Spooky22
$LRMR Thanks for the link. It was really interesting and makes me very confident, that we are invested in a company in very competent hands. She is crystal clear in Larimars challenges and how they are planning to address them. This will help tremendously with the FDA and if I should make a guess, I think it gets approved with some restrictions. If they can solve the occurences of Anaphylaxis and get approved ofc, this will become a jackpot imo. But again, our ceo makes me very confident, that we will get a good outcome of some sort, question is how good ;-)
6
BiotechStockFundManager
$LRMR Our Stocktwits watchers have officially crossed the 5,000 mark. That’s a real milestone, especially after hovering just below it for what seemed like ages. Great to see more eyes on the stock as we approach several more important milestones on the horizon. Exciting times ahead!
4
dento96
$LRMR silence will finally be broken next Tuesday at 10am et. Fireside chat. I would think quarter results before???
1
2
PaytiencePaysGreen
$LRMR gaslighting retailers for more than 2 years. What's new? Delay and dilution, D&D always! POS can't even maintain stock price when market is good
1
1
BiotechStockFundManager
$LRMR nice to see a lot of insider buying. A strong message to the market the company is confident with its future financing and approval.
3
longterminvs
$LRMR BOOM!! Thomas Hamilton bought 70K shares for his foundation. The guys amazing and on a mission.
3
SHVR89
$LRMR moving this to a core position. BLA is fully submitted, acceptance expected early 2027, approval mid-2027. I think it's a bit undervalued here and expect the repricing in H1 2027. Main risks are the anaphylaxis update in Q1 and financing terms only 13 patients vs natural history, not a controlled trial. With a sample that small the data can get better or worse as more patients come in. Market is real Skyclarys make a good revenue on it
3
Xanderzzzzzzz
$LRMR Nomlabofusp has received FDA Breakthrough Therapy Designation for the treatment of FA in adults and children as well as Fast Track, Rare Pediatric Disease, and Orphan Drug designations. Nomlabofusp was also selected for FDA’s Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, which has enabled more frequent interactions with FDA to support our development and regulatory strategy.
3
JoeSmith1812
$LRMR I realize the whole market is getting roasted, but any idea where earnings ran off to? I had today, pre-market, on my calendar. Also, appreciate your earlier posts. thanks
1
longterminvs
$LRMR Yeah, great overview. Great questions from the analyst. The CEO does an excellent job on these. Per kenny, she touched on finance needs, they need a couple of quarters, mentioned PRV, but she sounded very confident on financing through royalty deals from places they don't plan to commercialize the drug. She didn't seem to hesitate. That would be a big deal if no dilution. Any investor who didn't listent to it should listen to the replay. She is my favorite CEO for any Bio I own or have owned. Others I own the mgmt team can't work their way out of a wet paper bag.
1
Xanderzzzzzzz
$LRMR Potential Upcoming Milestones BLA Submission Acceptance: Early 2027 Open Label Study Safety Update: Q1 2027 U.S. Approval: Mid-2027 Obtaining & Monetizing the Rare Pediatric Disease Priority Review Voucher: Mid-2027, if approved U.S. Launch: Targeting Q3 2027 launch, if approved.
1
Spooky22
$LRMR A long wait??? I dont know how your investment stories normally go, but all those thing will probably happen in the next 6 months, if you want to bet on this company its now or never. In 6 months this company is either 10x or minus 70-80% imo. I am positive but nothing is certain ofc, this is biotech.
1
Rastaman2112
$LRMR I received a message to my phone that they are announcing results this morning. Is that true?
1
lowInCash
$LRMR what do you expect from this stock. Does recent jump from 2 to 3+ already priced everything till Q2 27?
Windy007
$LRMR Recommendations Larimar Therapeutics price target lowered to $9 from $11 at Wedbush LRMR | 7:35 AM Wedbush lowered the firm's price target on Larimar Therapeutics to $9 from $11 and keeps an Outperform rating on the shares. With the nomlabofusp BLA submission completed last week, the Q3 financial results release was a non-event for Larimar, the firm says. Most important in the near term is the BLA acceptance coming potentially in January, and PDUFA assignment
jsmerka
$LRMR hopefully they will find a financial partner to get them through commercialization without issuing a massive number of new shares.

Advertisement|Remove ads.